SCHEDULE: Ridgeback Capital Discloses 5.1% Stake in iTeos Therapeutics

Ridgeback Capital entities have reported a 5.1% beneficial ownership stake in iTeos Therapeutics, Inc., holding 1,942,959 common shares.

Summary

• Ridgeback Capital Investments L.P., Ridgeback Capital Investments LLC, and Ridgeback Capital Management LLC are the reporting persons.
• Collectively, these entities beneficially own 1,942,959 shares of iTeos Therapeutics, Inc. common stock.
• This ownership represents 5.1% of iTeos Therapeutics' outstanding common stock.
• The percentage is calculated based on 38,273,795 shares outstanding as of April 22, 2025, as reported by the company in its Form 10-Q filed on April 28, 2025.
• The reporting persons possess shared voting power and shared dispositive power over these 1,942,959 shares.
• The acquisition of these shares was not for the purpose of changing or influencing control of iTeos Therapeutics.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of a passive ownership stake by an institutional investor, providing factual information without inherently positive or negative operational news for the issuer.

Positives

• Ridgeback Capital, an institutional investor, has disclosed a significant 5.1% stake in iTeos Therapeutics, which may indicate confidence in the company's prospects.

Negatives

• No specific negative information regarding iTeos Therapeutics' operations or financial performance was disclosed in this Schedule 13G filing.

Risks

• The reporting persons disclaim beneficial ownership of the securities except to the extent of any pecuniary interest therein.
• The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding iTeos Therapeutics' future outlook.

Management Comments

• "The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the securities of iTeos Therapeutics, Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing represents a standard disclosure of a significant passive ownership stake by an institutional investor in a biotechnology company, common in the highly capital-intensive pharmaceutical and biotech sectors where institutional investment plays a crucial role in funding innovation and growth.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of a passive ownership stake and does not contain information for direct comparison to specific industry projects, financial results, or operational benchmarks of comparable companies.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings involving iTeos Therapeutics, Inc. were disclosed in this filing.

Related Party Transactions

• No related party transactions involving iTeos Therapeutics, Inc. were disclosed in this filing.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, potentially signaling investor confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact indicated by this beneficial ownership disclosure.

Next Steps

• No specific future actions or milestones for iTeos Therapeutics, Inc. were mentioned in this filing.

Key Dates

Keywords

iTeos Therapeutics, Ridgeback Capital, Schedule 13G, beneficial ownership, common stock, institutional investment, biotechnology, pharmaceuticals